Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

5 Aug 2003

Abstract excerpt

Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12915451
DOI: 10.1093/hmg/ddg256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophyPMID 12915451Read ↗

Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.Semantic proximity Read ↗

Spinal muscular atrophy: from gene to therapy.Semantic proximity Read ↗

Exclusion of Htra2-beta1, an up-regulator of full-length SMN2 transcript, as a modifying gene for spinal muscular atrophy.Semantic proximity Read ↗

Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA).Semantic proximity Read ↗

Valproic acid increases SMN levels in spinal muscular atrophy patient cellsSemantic proximity Read ↗

Htra2-β 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 ( SMN2 )Semantic proximity Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III.Semantic proximity Read ↗

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse modelsSemantic proximity Read ↗

VPA response in SMA is suppressed by the fatty acid translocase CD36Semantic proximity Read ↗

hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1Semantic proximity Read ↗

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compoundsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.